FGF23 and chronic kidney disease: Interventions such as erythropoiesis-stimulating agents and hypoxia-inducible factor prolyl hydroxylase inhibitors have shown promise in attenuating elevated FGF23 levels in CKD, with the added benefit of potentially reducing renal fibrosis markers (Noonan et al., 2020).